The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Landscape of functional DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs).
 
Rohit Thummalapalli
No Relationships to Disclose
 
Zeynep Tarcan
No Relationships to Disclose
 
Courtney Porfido
Employment - Pfizer (I)
 
Irina Linkov
No Relationships to Disclose
 
Umesh Bhanot
No Relationships to Disclose
 
Alissa Cooper
Honoraria - Ideology Health; Intellisphere; MedStar Health; MJH Life Sciences; Physician's Education Resource, LLC
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Regeneron
Research Funding - Abbvie (Inst); Amgen (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Salomon Tendler
No Relationships to Disclose
 
James Harding
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cogent Medicine; Elevar Therapeutics; Exelixis; Jazz Pharmaceuticals; Merck; RayzeBio; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Jazz Pharmaceuticals (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Tvardi Therapeutics (Inst); yivvia (Inst); Zymeworks (Inst)
 
Natasha Rekhtman
Honoraria - Merck
 
Charles Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Auron Therapeutics; Daiichi Sankyo/UCB Japan; DISCO; Earli; Genentech/Roche; Jazz Pharmaceuticals; Merck
Research Funding - Daiichi Sankyo (Inst); Merck (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Royalties related to licensing of anti-DLL3 antibodies.
 
Yelena Janjigian
Stock and Other Ownership Interests - Inspirna
Honoraria - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; eChinaHealth; Ed Med Resources (OncInfo); Eisai; Geneos; Genzyme; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; Imedex; Imugene; Inspirna; Lilly; Lynx Health; Master Clinician Alliance; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Research to Practice; Seagen; Silverback Therapeutics; Suzhou Liangyihui Network Technology; Talem Health; TotalCME; WebMD; Zymeworks
Consulting or Advisory Role - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; Ed Med Resources (OncLive); Eisai; Geneos; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; Imedex; Imugene; Inspirna; Jazz Pharmaceuticals; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Research to Practice; Seagen; Silverback Therapeutics; WebMD; Zymeworks
Research Funding - Arcus Biosciences (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Inspirna (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Stand up to Cancer (Inst); Transcenta (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Merck
Other Relationship - Axis Medical Education; Clinical Care Options; Giants of Cancer Care; Research to Practice
 
Heiko Schöder
Patents, Royalties, Other Intellectual Property - Memorial Sloan Kettering, my employer, has received royalty payments from Telix Pharmaceuticals. (Inst)
 
Jinru Shia
Consulting or Advisory Role - PAIGE.AI
 
Olca Basturk
No Relationships to Disclose
 
Nitya Raj
Consulting or Advisory Role - Crinetics Pharmaceuticals
Speakers' Bureau - ITM Oncologics
Research Funding - Camarus AB (Inst); Corcept Therapeutics (Inst); ITM Isotope Technologies Munich (Inst); Novartis (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Camurus
 
Jason Lewis
Leadership - pHLIP
Stock and Other Ownership Interests - Alpha-9; Clarity Pharmaceuticals; Evergreen Theragnostics; pHLIP; Summit Biomedical Imaging; Telix Pharmaceuticals
Consulting or Advisory Role - Alpha-9; Clarity Pharmaceuticals; InhibRx; Precirix; Sanofi
Research Funding - Novartis
Patents, Royalties, Other Intellectual Property - Clarity Pharmaceuticals; Daiichi Sankyo; Elucida Oncology, Inc; Macrocyclics, Inc; Theragnostics, Ltd
 
Lisa Bodei
Consulting or Advisory Role - Wren Laboratories
Research Funding - AAA/Endocyte/Novartis (Inst); AAA/Endocyte/Novartis (Inst); Abdera Thereapeutics (Inst); Advanced Accelerator Applications/Novartis (Inst); Fusion Pharmaceuticals (Inst); ITM Isotope Technologies Munich (Inst); Molecular Targeting Technologies (Inst); POINT Biopharma (Inst); RayzeBio (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis; Amgen; Clovis Oncology; Fusion Pharmaceuticals; Great Point Partners; IBA RadioPharma Solutions; ITM Isotope Technologies Munich; Molecular Targeting Technologies; POINT Biopharma; RayzeBio
 
Mark Dunphy
Patents, Royalties, Other Intellectual Property - Memorial Sloan Kettering Cancer Center holds the intellectual rights to PU-H71 and [124I]-PU-H71 (PCT/US06/03676, PCT/US2012/045861), which have been licensed to Samus Therapeutics. Dr. Dunphy has contributed to the patents and has received financial roya
 
Diane Reidy
Honoraria - Novartis
Consulting or Advisory Role - Chiasma; Exelixis; Wren laboratories
Research Funding - Ipsen; Merck; Novartis